当前位置： SCI文献检索 > United European Gastroenterology Journal期刊下所有文献 > Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis.

Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis.

Abstract：

BACKGROUND:Prucalopride is a selective, high-affinity, 5-hydroxytryptamine (serotonin) type 4 (5-HT4) receptor agonist with gastrointestinal prokinetic activities. This integrated analysis of data from three double-blind phase III trials (ClinicalTrials.gov: NCT00488137, NCT00483886, NCT00485940) compared the efficacy and safety of prucalopride 2 mg once daily in women with chronic constipation [≤2 spontaneous complete bowel movements (SCBM) per week] in whom laxatives had failed to provide adequate relief with that in the all-patient (AP) population of men and women with chronic constipation who had or had not obtained relief from laxatives. METHODS:Patients received prucalopride 2 mg or placebo once-daily for 12 weeks. Efficacy endpoints included an average of ≥3 SCBM/week and average increases of ≥1 SCBM/week and ≥1 SBM/week over this period. A response on any of these three endpoints was considered to be clinically relevant, and an overall response rate was derived for patients satisfying any of these endpoints. RESULTS:Of the AP population (n = 1318), 936 were women in whom laxatives had failed to provide adequate relief (WLF). More patients on prucalopride 2 mg than placebo had an average of ≥3 SCBM/week (AP 24.4 vs 11.0%; WLF 24.7 vs 9.2%), an average increase of ≥1 SCBM/week (AP 43.5 vs 24.8%; WLF 44.2 vs 22.6%), and an average increase of ≥1 SBM/week (AP 66.7 vs 38.4%; WLF 68.3 vs 37.0%) (all p < 0.001). Significant differences from placebo were evident in week 1 and sustained thereafter. Overall response rates in the AP and WLF populations, respectively, were 69.7 and 71.0% with prucalopride 2 mg and 44.5 and 41.6% with placebo (p < 0.001). Early (weeks 1-4) response predicted ultimate response over time. Common (>10%) adverse events were abdominal pain, nausea, diarrhoea, and headache. CONCLUSIONS:Prucalopride 2 mg once daily is effective in WLF. The efficacy and safety profile observed in WLF was similar to that in the total evaluated population of patients with chronic constipation who had or had not obtained adequate relief from laxatives.

journal_name

United European Gastroenterol J

journal_title

United European gastroenterology journal

authors

Tack J,Quigley E,Camilleri M,Vandeplassche L,Kerstens R

doi

10.1177/2050640612474651

subject

Has Abstract

pub_date

2013-02-01 00:00:00

pages

48-59

issue

eissn

2050-6406

issn

2050-6414

pii

10.1177_2050640612474651

journal_volume

pub_type

杂志文章

在线工具

Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis.